Implementing a new drug or technique (APA Cambridge 21. June 2013)

22
Implementing a new drug or technique (APA Cambridge 21. June 2013) Tom G. Hansen, MD, PhD, Department of Anaesthesia & Intensive Care Odense University Hospital & University of Southern Denmark DENMARK Email: [email protected]

description

Implementing a new drug or technique (APA Cambridge 21. June 2013). Tom G. Hansen, MD, PhD, Department of Anaesthesia & Intensive Care Odense University Hospital & University of Southern Denmark DENMARK Email: [email protected]. Tenets of evidence based- medicine. - PowerPoint PPT Presentation

Transcript of Implementing a new drug or technique (APA Cambridge 21. June 2013)

Page 1: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Implementing a new drug or technique (APA Cambridge 21. June 2013)

Tom G. Hansen, MD, PhD, Department of Anaesthesia & Intensive Care Odense University Hospital & University of Southern DenmarkDENMARKEmail: [email protected]

Page 2: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Tenets of evidence based- medicine

Page 3: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Hierarchy of evidence

1. Systematic review of RCTs2. A single RCT3. Observational studies4. Case series and reports

Page 4: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Two caveats……..

• Applicability of RCTs• Quality of evidence:

large observational study vs. a small RCT

Page 5: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Gap between need from public health perspective and what can be afforded

Page 6: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Slow implementation

Page 7: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Clinical guidelines

The WHO definition:……systematically developed evidence

based statements which asisst providers, recipients and other stakeholders to make informed decisions about appropriate health interventions…………

Page 8: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Clinical guidelines: - Aims• Appropriate care• Best available evidence • Multidisciplinary groups• Systematic and transparent concensus

processes• End-user involvement• Adaptations should be re-edited• Guidance of doctors• Do not replace knowledge and skills

Page 9: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

AGREE-II (www.agreetrust.org)23-point checklist: ….scope and purpose ….stakeholder involvement ….rigour of development ….clarity ….presentation ….applicability ….editorial independence

Page 10: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Guidelines - prosFacilitate EBMVariation in practiceDiscourage outdated practiceEfficiency healthcare↑ Freeing resources?Awareness on subjects↑Source of practical adviceStandardize clinical management

Page 11: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Guidelines - conDesigned for ”average” patients Implementation difficult:

- lack of expertise- disagreement- resources

Professional judgement Conflicts of interestExpensiveAuthorityDuplicationLack of relevant research of high qualityLegal consequences

Page 12: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Types of knowledge

→Explicit knowledge

→”tacit knowledge”

Page 13: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Requirements to guidelines• Support not constraint• Address practical questions• Short and concise• Standardized (e.g. AGREE-II)• New→ Why? Add? Divergence?• Evidense ↔ Expert opinion• Conflicts of interest• Reviewing• Revision

Page 14: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Who develops the guidelines?

• Local departments/hospitals• Cluster of hospitals• National• International/continental

Page 15: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

A simple clinical question!

Page 16: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Expensive new evidence

Page 17: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

The Fujii story

Page 18: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Retracted articles by Fujii 1991-2011

Page 19: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

New metaanalysis withut Fujii’s studies

Page 20: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Carlisle’s Conclusions

……………. if data with unusual distributions

are removed from meta-analysis and articles

by Fujii et al. excluded, then the antiemetic

effects of granisetron and ramosetron are

greatly reduced; further, there is no evidence

of synergism between antiemetics and

indeed, some evidence of antagonism

between antiemetic agents…………...

Page 21: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Conclusions• Transfer of research possible but success

varies• Gap between recommended and received

healthcare• Causes of knowing-doing gaps unknown• Complex and context dependent process• Need for assessment of interventions• Best implementation strategy unknown• Economics?

Page 22: Implementing a new drug or technique  (APA Cambridge 21. June 2013)

Aesop

After all is said and done.……..more is said than done…..